The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into reports of possible side effects.

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Aurobindo Pharma's CuraTeQ Biologics receives marketing authorization for Zefylti filgrastim biosimilar in the UK and EU.

EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator ...

The European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, ...

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...

Antibiotic use in the first 3 month of life was associated with a 23% increase in risk of early puberty in girls.

New research reveals the potential of drugs that have been on the market for decades to treat diseases other than those for ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

Ireland’s Health and Safety Executive has criticised a new report revealing the country’s shocking last place in Western Europe for new oncology drug access.

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...